Immune regulation by Tim-3 [version 1; referees: 2 approved]
T-cell immunoglobulin and mucin domain 3 (Tim-3) is a transmembrane protein that in both mice and humans has been shown to possess various functions in a context-dependent manner. Thus, Tim-3 has been associated with both inhibitory and co-stimulatory function, depending in part on the specific cell...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2018-03-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/7-316/v1 |
id |
doaj-cc1e1f9116d94e14ab6701135844b45e |
---|---|
record_format |
Article |
spelling |
doaj-cc1e1f9116d94e14ab6701135844b45e2020-11-25T03:06:39ZengF1000 Research LtdF1000Research2046-14022018-03-01710.12688/f1000research.13446.114602Immune regulation by Tim-3 [version 1; referees: 2 approved]Hridesh Banerjee0Lawrence P. Kane1Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USADepartment of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USAT-cell immunoglobulin and mucin domain 3 (Tim-3) is a transmembrane protein that in both mice and humans has been shown to possess various functions in a context-dependent manner. Thus, Tim-3 has been associated with both inhibitory and co-stimulatory function, depending in part on the specific cell type and immune response course. Though originally described on T cells, Tim-3 is now known to be expressed by both lymphoid and non-lymphoid cells within the immune system and even by non-immune cells. In addition, though widely thought of as a negative regulator of immunity, Tim-3 has been shown in more recent studies to have a positive function on both myeloid and lymphoid cells, including T cells. Tim-3 is often expressed at a high level on exhausted T cells in tumors and chronic infection and may engage in crosstalk with other so-called “checkpoint” molecules such as PD-1. Thus, Tim-3 has emerged as a possible therapeutic target, which is being actively explored both pre-clinically and clinically. However, recent research suggests a more complex in vivo role for this protein, compared with other targets in this area.https://f1000research.com/articles/7-316/v1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Hridesh Banerjee Lawrence P. Kane |
spellingShingle |
Hridesh Banerjee Lawrence P. Kane Immune regulation by Tim-3 [version 1; referees: 2 approved] F1000Research |
author_facet |
Hridesh Banerjee Lawrence P. Kane |
author_sort |
Hridesh Banerjee |
title |
Immune regulation by Tim-3 [version 1; referees: 2 approved] |
title_short |
Immune regulation by Tim-3 [version 1; referees: 2 approved] |
title_full |
Immune regulation by Tim-3 [version 1; referees: 2 approved] |
title_fullStr |
Immune regulation by Tim-3 [version 1; referees: 2 approved] |
title_full_unstemmed |
Immune regulation by Tim-3 [version 1; referees: 2 approved] |
title_sort |
immune regulation by tim-3 [version 1; referees: 2 approved] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2018-03-01 |
description |
T-cell immunoglobulin and mucin domain 3 (Tim-3) is a transmembrane protein that in both mice and humans has been shown to possess various functions in a context-dependent manner. Thus, Tim-3 has been associated with both inhibitory and co-stimulatory function, depending in part on the specific cell type and immune response course. Though originally described on T cells, Tim-3 is now known to be expressed by both lymphoid and non-lymphoid cells within the immune system and even by non-immune cells. In addition, though widely thought of as a negative regulator of immunity, Tim-3 has been shown in more recent studies to have a positive function on both myeloid and lymphoid cells, including T cells. Tim-3 is often expressed at a high level on exhausted T cells in tumors and chronic infection and may engage in crosstalk with other so-called “checkpoint” molecules such as PD-1. Thus, Tim-3 has emerged as a possible therapeutic target, which is being actively explored both pre-clinically and clinically. However, recent research suggests a more complex in vivo role for this protein, compared with other targets in this area. |
url |
https://f1000research.com/articles/7-316/v1 |
work_keys_str_mv |
AT hrideshbanerjee immuneregulationbytim3version1referees2approved AT lawrencepkane immuneregulationbytim3version1referees2approved |
_version_ |
1724673125159796736 |